LINC02352: A Potential Drug Target and Biomarker (G102725022)

Target Name: LINC02352

NCBI ID: G102725022

LINC02352

Other Name(s): Long intergenic non-protein coding RNA 2352 | long intergenic non-protein coding RNA 2352

LINC02352: A Potential Drug Target and Biomarker

Long intergenic non-protein coding RNAs (lncNPs) have emerged as a promising candidate for drug targeting and biomarker discovery due to their unique features, such as the ability to be targeted by small molecules, their robustness in gene expression, and their potential to interact with protein-coding RNAs. One of these lncNPs, LINC02352, has shown promising results in preclinical studies as a potential drug target and biomarker.

Expression and localization of LINC02352

LINC02352 is a 235-nt RNA molecule that is located between the intron-exon boundaries of genes 12 and 13 on chromosome 16. It is expressed in various tissues and cells, including brain, heart, liver, and pancreatic tissues, and has been shown to be highly expressed in cancer cells. LINC02352 has been localized to the nuclear specimen using RNA-seq and has been verified by Southern blotting.

Function and potential as a drug target

LINC02352 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. It has been shown to be involved in the regulation of cell adhesion, migration, and the Wnt signaling pathway. LINC02352 has also been shown to interact with the protein-coding RNA, PDGF-??, and has been predicted to interact with the PDGF receptor, PDGF-??, and SMAD4. These interactions suggest that LINC02352 may be a potential drug target for the treatment of various diseases associated with the PDGF signaling pathway, such as cancer, neurodegenerative diseases, and autoimmune diseases.

Function and potential as a biomarker

LINC02352 has also been shown to be a potential biomarker for various diseases. For example, LINC02352 has been shown to be downregulated in various cancer tissues and has been used as a negative control for the PDGF signaling pathway in cancer cells. It has also been shown to be upregulated in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and has been used as a potential biomarker for these diseases. Additionally, LINC02352 has been shown to be upregulated in individuals with heart disease and has been used as a potential biomarker for heart disease.

Methods to study LINC02352

In addition to its localization and function in various tissues, LINC02352 has also been studied using various techniques to confirm its potential as a drug target and biomarker. For example, LINC02352 has been shown to be a potential drug target by being targeted by small molecules and having a high interactivity with protein-coding RNAs, as predicted by the literature. To confirm its potential as a biomarker, LINC02352 has been used in various disease models, such as cancer and neurodegenerative diseases, and has been shown to have the potential to diagnose and monitor these diseases.

Conclusion

In conclusion, LINC02352 is a promising candidate for drug targeting and biomarker discovery due to its unique features, such as the ability to be targeted by small molecules, its robustness in gene expression, and its potential to interact with protein-coding RNAs. Its preclinical studies have shown that LINC02352 has the potential to be a valuable drug target and biomarker for the treatment of various diseases associated with the PDGF signaling pathway, including cancer, neurodegenerative diseases, and autoimmune diseases. Further studies are needed to confirm its potential and

Protein Name: Long Intergenic Non-protein Coding RNA 2352

The "LINC02352 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02352 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets